These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31597643)

  • 41. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
    Nedergaard MK; Michaelsen SR; Urup T; Broholm H; El Ali H; Poulsen HS; Stockhausen MT; Kjaer A; Lassen U
    PLoS One; 2015; 10(2):e0115315. PubMed ID: 25680186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
    Thomas AA; Fisher JL; Hampton TH; Christensen BC; Tsongalis GJ; Rahme GJ; Whipple CA; Steel SE; Davis MC; Gaur AB; Lewis LD; Ernstoff MS; Fadul CE
    Cancer Immunol Immunother; 2017 Mar; 66(3):379-389. PubMed ID: 27942839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
    Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
    JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
    Peterson TE; Kirkpatrick ND; Huang Y; Farrar CT; Marijt KA; Kloepper J; Datta M; Amoozgar Z; Seano G; Jung K; Kamoun WS; Vardam T; Snuderl M; Goveia J; Chatterjee S; Batista A; Muzikansky A; Leow CC; Xu L; Batchelor TT; Duda DG; Fukumura D; Jain RK
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4470-5. PubMed ID: 27044097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intratumoral VEGF nanotrapper reduces gliobastoma vascularization and tumor cell mass.
    Sousa F; Costa-Pereira AI; Cruz A; Ferreira FJ; Gouveia M; Bessa J; Sarmento B; Travasso RDM; Mendes Pinto I
    J Control Release; 2021 Nov; 339():381-390. PubMed ID: 34592385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
    Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
    Wang N; Jain RK; Batchelor TT
    Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiangiogenic therapy for glioblastoma.
    Gerstner ER; Batchelor TT
    Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
    Schmittnaegel M; Rigamonti N; Kadioglu E; Cassará A; Wyser Rmili C; Kiialainen A; Kienast Y; Mueller HJ; Ooi CH; Laoui D; De Palma M
    Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
    Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
    Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
    Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
    Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma.
    Verhoeff JJ; Stalpers LJ; Claes A; Hovinga KE; Musters GD; Peter Vandertop W; Richel DJ; Leenders WP; van Furth WR
    Eur J Cancer; 2009 Nov; 45(17):3074-80. PubMed ID: 19734041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 57. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
    Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranai Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
    Brain Tumor Pathol; 2024 Apr; 41(2):61-72. PubMed ID: 38619734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apelin Controls Angiogenesis-Dependent Glioblastoma Growth.
    Frisch A; Kälin S; Monk R; Radke J; Heppner FL; Kälin RE
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32545380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
    Lee J; Kim E; Ryu SW; Choi C; Choi K
    J Neurooncol; 2016 May; 128(1):29-34. PubMed ID: 26951556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
    Einstein DJ; McDermott DF
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):478-488. PubMed ID: 28749908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.